

Candriam Equities L Europe Innovation

Market Overview

Equity markets opened the new year on a strong note. The inauguration of the new US President was probably the most impacting event in the first month of the year. Even if investors were not sure about the consequences of President Trump's "Make America Great Again" plans, it was widely accepted that the impact on US economic growth would be positive, at least in the short term.

In Europe, company results were very strong, economic growth seems a little bit more resilient than feared and the inflation trajectory is such that the ECB can continue to lower rates. In this environment, the European stock market significantly outperformed. Gains were supported by the Financials and Consumer Discretionary sectors owing to the solid global economic backdrop and tentative signs of improvement in the euro zone macro data.

The European Central Bank cut its policy rate by 25bp to 2.75% this month. It still saw this level as restrictive and the December staff forecasts were seen as "on track". The latter have rate cuts down to 2% factored in, suggesting that the ECB is on a path to delivering those. President Lagarde confirmed the lower range for the neutral rate of 1.75%-2.25% she gave recently, suggesting room to cut further before a debate about moving into accommodation has to occur.

Portfolio Highlights

European equities market started strongly 2025 with a positive performance in January. The month was marked by the emergence of DeepSeek, a new Chinese AI, raising questions about the US tech sector's ability to meet high expectations. In the long run, technological evolution might play a more decisive role than politics in shaping market leadership.

The fund has a good start of the year with outperformance during the month.

Our key positive contributors were Hexagon, Carl Zeiss Meditec and bioMérieux. On the other hand, our main performance detractors include Kingspan, DSM and Symrise.

During the month, we continued to trim the allocation towards EssilorLuxottica. We still like the LT fundamentals and multiples growth drivers (smart glasses, myopia management, Nuance Audio Glasses) but feel valuation is more stretched at these levels.

Fund Outlook

The environment should be more favourable to our portfolio given the ongoing rate-cutting cycle from the ECB, which should enable Quality / Growth companies to benefit from better valuation metrics and lower financing conditions. We are confident that long-term rates will not increase in Europe despite a likely different trajectory in the US following the Trump victory.

The stimulus plan in China will be positive for some companies in the portfolio (especially within Healthcare equipment), although measures still need to be detailed. We still think that cyclical sectors (Industrials, Consumer Discretionary and Financials) are expensive.

Some European cyclical names with high US exposure, especially within Industrials, will benefit from Donald Trump's upcoming tax cuts. On the other hand, other names (within Automobiles for instance) will be hit by higher US tariffs on European products.

The risk of higher US tariffs is limited because the vast majority of goods sold by European companies in the US are manufactured directly on American soil, and not subject to customs. The damage from higher tariffs would be significant for only a handful of sectors with European production, such as luxury goods and automobiles.

For 2025, in line with our soft-landing scenario of the global economy, we expect Quality / Growth stocks (and particularly Innovative companies) to outperform.

This marketing communication is provided for information purposes only, it does not constitute an offer to buy or sell financial instruments, nor does it represent an investment recommendation or confirm any kind of transaction, except where expressly agreed. Although Candriam selects carefully the data and sources within this document, errors or omissions cannot be excluded a priori. Candriam cannot be held liable for any direct or indirect losses as a result of the use of this document. The intellectual property rights of Candriam must be respected at all times, contents of this document may not be reproduced without prior written approval.

Warning: Past performance of a given financial instrument or index or an investment service or strategy, or simulations of past performance, or forecasts of future performance does not predict future returns. Gross performances may be impacted by commissions, fees and other expenses. Performances expressed in a currency other than that of the investor's country of residence are subject to exchange rate fluctuations, with a negative or positive impact on gains. If the present document refers to a specific tax treatment, such information depends on the individual situation of each investor and may change.

In respect to money market funds, please be aware that an investment in a fund is different from an investment in deposits and that the investment's principal is capable of fluctuation. The fund does not rely on external support for guaranteeing its liquidity or stabilizing its NAV per unit or share. The risk of loss of the principal is borne by the investor.

Candriam consistently recommends investors to consult via our website www.candriam.com the key information document, prospectus, and all other relevant information prior to investing in one of our funds, including the net asset value ("NAV") of the funds. Investor rights and complaints procedure, are accessible on Candriam's dedicated regulatory webpages <https://www.candriam.com/en/professional/legal-and-disclaimer-candriam/regulatory-information/>. This information is available either in English or in local languages for each country where the fund's marketing is approved. According to the applicable laws and regulations, Candriam may decide to terminate the arrangements made for the marketing of a relevant fund at any time.

Information on sustainability-related aspects: the information on sustainability-related aspects contained in this communication are available on Candriam webpage <https://www.candriam.com/en/professional/market-insights/sfd/>. The decision to invest in the promoted product should take into account all the characteristics or objectives of the promoted product as described in its prospectus, or in the information documents which are to be disclosed to investors in accordance with the applicable law.

Notice to investors in Switzerland: The information provided herein does not constitute an offer of financial instruments in Switzerland pursuant to the Swiss Financial Services Act ("FinSA") and its implementing ordinance. This is solely an advertisement pursuant to FinSA and its implementing ordinance for financial instruments.

Swiss representative: CACEIS (Switzerland) SA, Route de Signy 35, CH-1260 Nyon. The legal documents as well as the latest annual and semi-annual financial reports, if any, of the investment funds may be obtained free of charge from the Swiss representative.

Swiss paying agent: CACEIS Bank, Paris, succursale de Nyon/Suisse, Route de Signy, 35, CH-1260 Nyon. Place of performance: Route de Signy 35, CH-1260 Nyon. Place of jurisdiction: Route de Signy 35, CH-1260 Nyon.

Specific information for investors in France: the appointed representative and paying agent in France is CACEIS Bank, Luxembourg Branch, sis 1-3, place Valhubert, 75013 Paris, France. The prospectus, the key investor information, the articles of association or as applicable the management rules as well as the annual and semi-annual reports, each in paper form, are made available free of charge at the representative and paying agent in France.

Specific information for investors in Spain: Candriam Sucursal en España has its registered office at C/ Pedro Teixeira, 8, Edif. Iberia Mart I, planta 4, 28020 Madrid and is registered with the Comisión Nacional del Mercado de Valores (CNMV) as an European Economic Area management company with a branch. CNMV: 233